Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-26
2011-04-26
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S423000, C546S226000, C548S540000
Reexamination Certificate
active
07932269
ABSTRACT:
The present invention is concerned with novel sulfonamides of formulawherein R1, R2, R3and n are as described in the description and claims. The compounds are orexin receptor antagonists, useful in the treatment of disorders, in which orexin pathways are involved.
REFERENCES:
patent: 7312358 (2007-12-01), Quattropani et al.
patent: 2007/0185136 (2007-08-01), Courtemanche
patent: WO 02/32864 (2002-04-01), None
Siegel, Annu. Rev. Psychol. vol. 55, pp. 125-148 (2004).
De Lecea et al., Proc. Natl. Acad. Sci. USA vol. 95 pp. 322-327 (1998).
Sakurai et al., Cell vol. 92 pp. 573-585 (1998).
Sakurai, T., Regulatory Peptides vol. 126 pp. 3-10 (2005).
Peyron et al., J. Neurosci. vol. 18 pp. 9996-10015 (1998).
Nambu et al., Brain Res. vol. 827 pp. 243-260 (1999).
Chemelli et al., Cell, vol. 98 pp. 437-451 (1999).
Lin et al., Cell, vol. 98 pp. 365-376 (1999).
Nishino et al., Lancet vol. 355 pp. 39-40 (2000).
Peyron et al., Nature Medicine vol. 6 pp. 991-997 (2000).
Mignot et al., Sleep vol. 11, pp. 1012-1020 (1997).
Piper et al., Eur. J. Neuroscience vol. 12 pp.726-730 (2000).
Sakamoto et al., Regul. Pept. vol. 118 pp. 183-191 (2004).
Ida et al., Biochem. Biophys. Res. Comm. vol. 270 pp. 318-323 (2000).
Kuru at al., Neuroreport vol. 11 pp. 1977-1980 (2000).
Winsky-Sommerer et al., J. Neuroscience vol. 24 pp. 11439-11448 (2004).
Chang et al., Neurosci. Res. pp. 356-362 (2006).
Suzuki et al., Brain Research vol. 1044 pp. 116-121 (2005).
Digby et al., J. Endocrinol. vol. 191 pp. 129-136 (2006).
Cai at al., Expert Opin. Ther. Patents vol. 16(5) pp. 631-646 (2006).
Bingham et al., Current Opinion in Drug Discovery & Development vol. 9(5) pp. 551-559 (2006).
Bourgin et al., J. Neurosci. vol. 20(20) pp. 7760-7765 (2000).
Smith et al.,Neurosci. Lett vol. 341(3) pp. 256-258 (2003).
Quattropani et al., Journal of Medicinal Chemistry vol. 48(24) pp. 7882-7905 (2005).
Malherbe et al., Mol. Pharmacol. vol. 64 pp. 823-832 (2003).
Yang et al,Bioorganic&Medicinal Chemistry Letters, (2008) 1340-1345 18:4 XP022479328.
Database Beilstein, XP002525000 Accessin No. 9336940, 2009.
Aissaoui H et al,Bioroganic&Medicianl Chemistry Letters, (2008) XP025562032, 18:21, 5729-5733.
Knust Henner
Nettekoven Matthias
Pinard Emmanuel
Roche Olivier
Rogers-Evans Mark
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
Saeed Kamal A
LandOfFree
Sulfonamides as orexin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonamides as orexin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamides as orexin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2636892